Showing 1,261 - 1,280 results of 3,189 for search '"vaccination"', query time: 0.07s Refine Results
  1. 1261
  2. 1262
  3. 1263
  4. 1264

    Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis by Christian Gluud, Marija Barbateskovic, Sara Russo Krauss, Janus C Jakobsen, Sesilje Bondo Petersen, Sarah Louise Klingenberg, Snezana Djurisic, Mette Kenfelt, De Zhao Kong

    Published 2022-06-01
    “…Objectives To assess the benefits and harms of aluminium adjuvants versus placebo or no intervention in randomised clinical trials in relation to human vaccine development.Design Systematic review with meta-analysis and trial sequential analysis assessing the certainty of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE).Data sources We searched CENTRAL, MEDLINE, Embase, LILACS, BIOSIS, Science Citation Index Expanded and Conference Proceedings Citation Index-Science until 29 June 2021, and Chinese databases until September 2021.Eligibility criteria Randomised clinical trials irrespective of type, status and language of publication, with trial participants of any sex, age, ethnicity, diagnosis, comorbidity and country of residence.Data extraction and synthesis Two independent reviewers extracted data and assessed risk of bias with Cochrane’s RoB tool 1. …”
    Get full text
    Article
  5. 1265

    Efficacy of Streptococcus agalactiae vaccine strains N3M and N4M in fry tilapia infected by different strains of S. agalactiae by Sukenda, Sukenda, Arif Lukman Firmansyah, Rahman, Rahman, Sri Nuryati, Dendi Hidayatullah

    Published 2018-07-01
    “…The result of antibody level in vaccinated fish after vaccination of N3M, N4M vaccine, N3M and N4M control were 0.767; 0.743; 0.587; and 0.544, respectively. …”
    Get full text
    Article
  6. 1266
  7. 1267
  8. 1268
  9. 1269
  10. 1270

    Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants by Odile Launay, Rachna Gupta, Tifany Machabert, Eleine Konate, Alexandra Rousseau, Claire Vigne, Francois Beckers, Louis Devlin, Elisabeth Botelho-Nevers, Marine Cachanado, Christian Chidiac, Dominique Deplanque, Bertrand Dussol, Inès Ben Ghezala, Marie Lachatre, Karine Lacombe, Fabrice Laine, Liem Binh Luong Nguyen, Patricia Pavese, Catherine Schmidt-Mutter, Marie-Pierre Tavolacci, Roman M. Chicz, Bogdana Coudsy, Saranya Sridhar, Amel Touati, Eric Tartour, Tabassome Simon

    Published 2025-01-01
    “…Abstract Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). …”
    Get full text
    Article
  11. 1271

    Plasmodium falciparum surf4.1 in clinical isolates: From genetic variation and variant diversity to in silico design immunopeptides for vaccine development. by Nitchakarn Noranate, Jariya Sripanomphong, Fingani Annie Mphande-Nyasulu, Suwanna Chaorattanakawee

    Published 2024-01-01
    “…SURFINs protein family expressed on surface of both infected red blood cell and merozoite surface making them as interesting vaccine candidate for erythrocytic stage of malaria infection. …”
    Get full text
    Article
  12. 1272

    Immune Thrombocytopenic Purpura following Administration of mRNA-Based SARS-CoV-2 and MMR Vaccinations: A Cautionary Tale by Whitney Thomas, Adam Albano, Dean Kirkel, Nason Rouhizad, Folasade Arinze

    Published 2021-01-01
    “…We report a case of immune thrombocytopenic purpura (ITP) in an otherwise healthy 31-year-old man following coadministration of the live measles, mumps, and rubella (MMR) vaccine with the Pfizer-BioNTech mRNA SARS-CoV-2 vaccine. …”
    Get full text
    Article
  13. 1273

    About Partial Reachability Issues in an SEIR Epidemic Model and Related Infectious Disease Tracking in Finite Time under Vaccination and Treatment Controls by Manuel De la Sen, Asier Ibeas, Raul Nistal

    Published 2021-01-01
    “…This paper studies some basic properties of an SEIR (Susceptible-Exposed-Infectious-Recovered) epidemic model subject to vaccination and treatment controls. Firstly, the basic stability, boundedness, and nonnegativity of the state trajectory solution are investigated. …”
    Get full text
    Article
  14. 1274
  15. 1275
  16. 1276
  17. 1277

    METHOD FOR FMD VIRUS 146S COMPONENT CONCENTRATION DETERMINATION WITH REAL-TIME REVERSE TRANSCRIPTION – POLYMERASE CHAIN REACTION IN VACCINE RAW MATERIALS by M. I. Doronin, A. M. Timina, D. A. Lozovoy, V. A. Starikov, D. V. Mikhalishin, N. N. Medvedeva, А. V. Borisov

    Published 2018-07-01
    “…It has been experimentally proven that the quantity of the 146S component determined by the real-time RT-PCR method using developed regression model and contained in the inoculation dose of FMD vaccine confers protection to the vaccinated animals against generalized FMD of A, O, Asia-1 types. rtRT-PCR method is highly sensitive and allows rapid and highly reliable estimation of  the 146S antigen concentration in FMD vaccine. …”
    Get full text
    Article
  18. 1278
  19. 1279

    A subunit vaccine Ag85A-LpqH focusing on humoral immunity provides substantial protection against tuberculosis in mice by Lingyuan Zeng, You Zuo, Minghui Tang, Chengrui Lei, Huoming Li, Xiuling Ma, Jiahong Ji, Hao Li

    Published 2025-01-01
    “…This vaccine can induce robust antibody responses, as well as T cell immune responses especially strong CD8+ T cell responses. …”
    Get full text
    Article
  20. 1280